STI-571 inhibits in vitro angiogenesis
- 10 September 2003
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 310 (1) , 135-142
- https://doi.org/10.1016/j.bbrc.2003.08.129
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Complete Molecular Remission in Chronic Myelogenous Leukemia after Imatinib TherapyNew England Journal of Medicine, 2002
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- Tumor Regression by Targeted Gene Delivery to the NeovasculatureScience, 2002
- Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapyCancer, 2002
- STI571 (Gleevec™) as a paradigm for cancer therapyTrends in Molecular Medicine, 2002
- Inhibition of KIT Tyrosine Kinase Activity: A Novel Molecular Approach to the Treatment of KIT-Positive MalignanciesJournal of Clinical Oncology, 2002
- Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement.International Journal of Cancer, 2001
- Kringle 5 of Plasminogen is a Novel Inhibitor of Endothelial Cell GrowthJournal of Biological Chemistry, 1997
- Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cellsNature Medicine, 1996
- Angiostatin: A Circulating Endothelial Cell Inhibitor That Suppresses Angiogenesis and Tumor GrowthCold Spring Harbor Symposia on Quantitative Biology, 1994